AstraZeneca (AZN) Given Hold Rating at Jefferies Financial Group
Jefferies Financial Group reissued their hold rating on shares of AstraZeneca (LON:AZN) in a report published on Friday. Jefferies Financial Group currently has a GBX 5,800 ($75.79) price target on the biopharmaceutical company’s stock.
AZN has been the topic of several other research reports. Barclays restated an overweight rating and issued a GBX 6,600 ($86.24) target price (up previously from GBX 6,500 ($84.93)) on shares of AstraZeneca in a report on Friday, August 10th. Deutsche Bank restated a buy rating and issued a GBX 6,000 ($78.40) target price (up previously from GBX 5,700 ($74.48)) on shares of AstraZeneca in a report on Friday, July 13th. Credit Suisse Group set a GBX 5,900 ($77.09) target price on shares of AstraZeneca and gave the stock a buy rating in a report on Friday, July 27th. Liberum Capital restated a hold rating on shares of AstraZeneca in a report on Friday, August 31st. Finally, JPMorgan Chase & Co. set a GBX 5,800 ($75.79) target price on shares of AstraZeneca and gave the stock a buy rating in a report on Friday, July 20th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of Hold and an average price target of GBX 5,700.70 ($74.49).
Shares of AZN traded down GBX 70 ($0.91) on Friday, hitting GBX 5,546 ($72.47). 2,077,869 shares of the stock traded hands, compared to its average volume of 2,310,000. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: What is insider trading?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.